Abstract
Osteoporosis is a serious health problem worldwide that is associated with an increased risk of fractures and mortality. Vascular calcification is a well-defined independent risk factor for cardiovascular disease (CVD) and mortality. Major advances in our understanding of the pathophysiology of osteoporosis and vascular calcification indicate that these two processes share common pathogenetic mechanisms. Multiple factors including proteins (such as bone morphogenetic proteins, receptor activator of nuclear factor κB ligand, osteoprotegerin, matrix Gla protein and cathepsins), parathyroid hormone, phosphate, oxidized lipids and vitamins D and K are implicated in both bone and vascular metabolism, illustrating the interaction of these two, seemingly unrelated, conditions. Many clinical studies have now confirmed the correlation between osteoporosis and vascular calcification as well as the increased risk of CVD in patients with osteoporosis. Here, we explore the proposed mechanistic similarities between osteoporosis and vascular calcification and present an overview of the clinical data that support the interaction between these conditions.
Key Points
-
Osteoporosis and vascular calcification share common pathogenetic mechanisms, involving bone morphogenetic proteins, the RANKL–RANK–OPG pathway, MGP and vitamin K
-
Patients with osteoporosis have higher levels of vascular calcification than those with normal bone mineral density
-
Clinical evidence reveals that osteoporosis is associated with cardiovascular events and increased mortality; moreover, vascular calcification is related to an increased risk of fracture
-
In patients with osteoporosis, cardiac and/or vascular calcification can be easily detected by use of simple screening tests, such as ultrasonography of the heart and carotid arteries, or thoracic and abdominal radiography
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Reginster, J. Y. & Burlet, N. Osteoporosis: a still increasing prevalence. Bone 38 (Suppl.), S4–S9 (2006).
Sweet, M. G., Sweet, J.M., Jeremiah, M.P. & Galazka, S. S. Diagnosis and treatment of osteoporosis. Am. Fam. Physician 79, 193–200 (2009).
Sambrook, P. & Cooper, C. Osteoporosis. Lancet 367, 2010–2018 (2006).
Cummings, S.R. & Melton, L. J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359, 1761–1767 (2002).
Greenland, P. et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation 115, 402–426 (2007).
Demer, L. L. & Tintut, Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 117, 2938–2948 (2008).
Wilson, P. W. et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 103, 1529–1534 (2001).
Tan, S. D. et al. Osteocytes subjected to fluid flow inhibit osteoclast formation and bone resorption. Bone 41, 745–751 (2007).
Eriksen, E. F. Cellular mechanisms of bone remodeling. Rev. Endocr. Metab. Disord. 11, 219–227 (2010).
Radi, Z. A., Guzman, R. E. & Bell, R. R. Increased connective tissue extracellular matrix in the op/op model of osteopetrosis. Pathobiology 76, 199–203 (2008).
Teitelbaum, S. L. Osteoclasts: what do they do and how do they do it? Am. J. Pathol. 170, 427–435 (2007).
Feskanich, D. et al. Vitamin K intake and hip fractures in women: a prospective study. Am. J. Clin. Nutr. 69, 74–79 (1999).
Szulc, P., Chapuy, M. C., Meunier, P. J. & Delmas, P. D. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J. Clin. Invest. 91, 1769–1774 (1993).
Luukinen, H. et al. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J. Bone Miner. Res. 15, 2473–2478 (2000).
Knapen, M. H., Nieuwenhuijzen Kruseman, A. C., Wouters, R. S. & Vermeer, C. Correlation of serum osteocalcin fractions with bone mineral density in women during the first 10 years after menopause. Calcif. Tissue Int. 63, 375–379 (1998).
London, G. M. et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 18, 1731–1740 (2003).
Guzman, R. J. Clinical, cellular and molecular aspects of arterial calcification. J. Vasc. Surg. 45 (Suppl. A), A57–A63 (2007).
Smith, E. R. et al. Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease. Hypertension 59, 973–978 (2012).
Willens, H. J. et al. The relation between mitral annular calcification and mortality in patients undergoing diagnostic coronary angiography. Echocardiography 23, 717–722 (2006).
Ross, E. A. Evolution of treatment strategies for calciphylaxis. Am. J. Nephrol. 34, 460–467 (2011).
Libby, P. & Theroux P. Pathophysiology of coronary artery disease. Circulation 111, 3481–3488 (2005).
Shao, J. S., Cheng, S. L., Sadhu, J. & Towler, D. A. Inflammation and the osteogenic regulation of vascular calcification: a review & perspective. Hypertension 55, 579–592 (2010).
Nakano-Kurimoto, R. et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am. J. Physiol. Heart Circ. Physiol. 297, 1673–1684 (2009).
Vattikuti, R. & Towler, D. A. Osteogenic regulation of vascular calcification: an early perspective. Am. J. Physiol. Endocrinol. Metab. 286, 686–696 (2004).
Rajamannan, N. M. et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107, 2181–2184 (2003).
Osman, L., Yacoub, M. H., Latif, N., Amrani, M. & Chester, A. H. Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation 114, 1547–1552 (2006).
Farrington-Rock, C. et al. Chondrogenic and adipogenic potential of microvascular pericytes. Circulation 110, 2226–2232 (2004).
Rennenberg, R. J. et al. Calcium scores and matrix Gla protein levels: association with vitamin K status. Eur. J. Clin. Invest. 40, 344–349 (2010).
Gazzerro, E., Rydziel, S. & Canalis, E. Skeletal bone morphogenetic proteins suppress the expression of collagenase-3 by rat osteoblasts. Endocrinology 140, 562–567 (1999).
Boden, S. D. et al. Glucocorticoid-induced differentiation of fetal rat calvarial osteoblasts is mediated by bone morphogenetic protein-6. Endocrinology 138, 2820–2828 (1997).
Csiszar, A. et al. Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype. Am. J. Pathol. 168, 629–638 (2006).
Ungvari, Z. et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-α, NAD(P)H oxidase and inducible nitric oxide synthase. Arterioscler. Thromb. Vasc. Biol. 23, 418–424 (2003).
Towler, D. A., Bidder, M., Latifi, T., Coleman, T. & Semenkovich, C. F. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J. Biol. Chem. 273, 30427–30434 (1998).
Csiszar, A., Labinskyy, N., Jo, H., Ballabh, P. & Ungvari, Z. Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 295, H569–H577 (2008).
Mathew, S. et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J. Am. Soc. Nephrol. 19, 1092–1105 (2008).
Szymczyk, K. H., Freeman, T. A., Adams, C. S., Srinivas, V. & Steinbeck, M. J. Active caspase-3 is required for osteoclast differentiation. J. Cell. Physiol. 209, 836–844 (2006).
Kearns, A. E., Khosla, S. & Kostenuik, P. J. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 29, 155–192 (2008).
Sobue, T. et al. Tissue inhibitor of metalloproteinases 1 and 2 directly stimulate the bone-resorbing activity of isolated mature osteoclasts. J. Bone Miner. Res. 16, 2205–2214 (2001).
Hofbauer, L. C. et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140, 4367–4370 (1999).
Sandberg, W. J. et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler. Thromb. Vasc. Biol. 26, 857–863 (2006).
Kiechl, S. et al. Soluble receptor activator of nuclear factor-κB ligand and risk for cardiovascular disease. Circulation 116, 385–391 (2007).
Shargorodsky, M. et al. Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis 204, 608–611 (2009).
Kiechl, S. et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109, 2175–2180 (2004).
Browner, W. S., Lui, L. Y. & Cummings, S. R. Association of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J. Clin. Endocrinol. Metab. 86, 631–637 (2001).
Emery, J. G. et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363–14367 (1998).
Morony, S. et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in Ldlr(−/−) mice. Circulation 117, 411–420 (2008).
Krishnan, V., Bryant, H. U. & MacDougald, O. A. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116, 1202–1209 (2006).
Veverka V. et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J. Biol. Chem. 284, 10890–10900 (2009).
Voskaridou E. et al. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 94, 725–728 (2009).
Wang F. S. et al. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss: a histomorphological study in ovariectomized rats. Bone 40, 485–492 (2007).
Politou, M. et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int. J. Cancer 119, 1728–1731 (2006).
Voorzanger-Rousselot, N. et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br. J. Cancer 97, 964–970 (2007).
Yao, W. et al. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 58, 1674–1686 (2008).
Ohnaka, K., Tanabe, M., Kawate, H., Nawata, H. & Takayanagi, R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem. Biophys. Res. Commun. 329, 177–181 (2005).
Jia, D., O'Brien, C. A., Stewart, S. A., Manolagas, S. C. & Weinstein, R. S. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147, 5592–5599 (2006).
Shao, J. S. et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J. Clin. Invest. 115, 1210–1220 (2005).
Ketteler, M. et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361, 827–833 (2003).
Ix, J. H. et al. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115, 2533–2539 (2007).
Suttamanatwong, S. et al. Sp proteins and Runx2 mediate regulation of matrix Gla protein (MGP) expression by parathyroid hormone. J. Cell. Biochem. 107, 284–292 (2009).
Eferl, R. et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J. 23, 2789–2799 (2004).
Jono, S. et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb. Haemost. 91, 790–794 (2004).
Ueland, T. et al. Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J. Intern. Med. 268, 483–492 (2010).
Schurgers, L. J. et al. The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin. J. Am. Soc. Nephrol. 5, 568–575 (2010).
Osako, M. K. et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ. Res. 107, 466–475 (2010).
Nofer, J. R. Estrogens and atherosclerosis: insights from animal models and cell systems. J. Mol. Endocrinol. 48, R13–R29 (2012).
Sumino, H. et al. Relationship between brachial arterial endothelial function and lumbar spine bone mineral density in postmenopausal women. Circ. J. 71, 1555–1559 (2007).
Booth, S. L. et al. Vitamin K intake and bone mineral density in women and men. Am. J. Clin. Nutr. 77, 512–516 (2003).
Hart, J. P. et al. Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis. J. Clin. Endocrinol. Metab. 60, 1268–1269 (1985).
Hodges, S. J, Akesson, K., Vergnaud, P., Obrant, K. & Delmas, P. D. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J. Bone Miner. Res. 8, 1241–1245 (1993).
Cranenburg, E. C. et al. The circulating inactive form of matrix Gla protein (ucMGP) as a biomarker for cardiovascular calcification. J. Vasc. Res. 45, 427–436 (2008).
Geleijnse, J. M. et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam Study. J. Nutr. 134, 3100–3105 (2004).
Gast, G. C. et al. A high menaquinone intake reduces the incidence of coronary heart disease. Nutr. Metab. Cardiovasc. Dis. 19, 504–510 (2009).
Shea, M. K. et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am. J. Clin. Nutr. 89, 1799–1807 (2009).
Bolland, M. J. et al. Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ 336, 262–266 (2008).
Schurgers, L. J., Aebert, H., Vermeer, C., Bültmann, B. & Janzen, J. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 104, 3231–3232 (2004).
Price, P. A., Faus, S. A. & Williamson, M. K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler. Thromb. Vasc. Biol. 18, 1400–1407 (1998).
Hruska, K. A., Mathew, S., Lund, R., Qiu, P. & Pratt, R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 74, 148–157 (2008).
Hagström, E. et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119, 2765–2771 (2009).
Li, X., Yang, H. Y. & Giachelli, C. M. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ. Res. 98, 905–912 (2006).
Skoumal, M. et al. Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction. Arthritis Res. Ther. 7, R65–R70 (2005).
Perez-Castrillon, J. L., Pinacho, F., De Luis, D., Lopez-Menendez, M. & Laita, A. D. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women. J. Osteoporos. http://dx.doi.org/10.4061/2010/401581.
Kitamoto, S. et al. Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation 115, 2065–2075 (2007).
Lutgens, E. et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 113, 98–107 (2006).
Asou, Y. et al. Osteoponotin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology 142, 1325–1332 (2001).
Scatena, M., Liaw, L. & Giachelli, C. M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler. Thromb. Vasc. Biol. 27, 2302–2309 (2007).
Speer, M. Y. et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J. Exp. Med. 196, 1047–1055 (2002).
Kadoglou, N. P. et al. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J. Vasc. Surg. 47, 55–62 (2008).
Wada, T., McKee, M. D., Steitz, S. & Giachelli, C. M. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ. Res. 84, 166–178 (1999).
Suzuki, A., Sekiguchi, S., Asano, S. & Itoh, M. Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis. J. Pharmacol. Sci. 106, 530–535 (2008).
Huang, M. S., Sage, A. P., Lu, J., Demer, L. L. & Tintut, Y. Phosphate and pyrophosphate mediate PKA-induced vascular cell calcification. Biochem. Biophys. Res. Commun. 374, 553–558 (2008).
Tintut, Y., Patel, J., Parhami, F. & Demer, L. L. Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102, 2636–2642 (2000).
Tintut, Y., Parhami, F., Boström, K., Jackson, S. M. & Demer, L. L. cAMP stimulates osteoblast-like differentiation of calcifying vascular cells: potential signaling pathway for vascular calcification. J. Biol. Chem. 273, 7547–7553 (1998).
Mizobuchi, M., Finch, J. L., Martin, D. R. & Slatopolsky, E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 72, 709–715 (2007).
Bas, A., Lopez, I., Perez, J., Rodriguez, M. & Aquilera-Tejero, E. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J. Bone Miner. Res. 21, 484–490 (2006).
Demer, L. L. A skeleton in the atherosclerosis closet. Circulation 92, 2029–2032 (1995).
Somjen, D. et al. 25-hydroxyvitamin D3-1α-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111, 1666–1671 (2005).
Parhami, F. et al. Atherogenic high-fat diet reduces bone mineralization in mice. J. Bone Miner. Res. 16, 182–188 (2001).
Parhami, F., Garfinkel, A. & Demer, L. L. Role of lipids in osteoporosis. Arterioscler. Thromb. Vasc. Biol. 20, 2346–2348 (2000).
Tintut, Y., Morony, S. & Demer, L. L. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler. Thromb. Vasc. Biol. 24, 6–10 (2004).
Parhami, F. et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation: a possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 17, 680–687 (1997).
Yamaguchi, T. et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr. J. 49, 211–217 (2002).
Mundy, G. et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946–1949 (1999).
Edwards, C. J., Hart, D. J. & Spector, T. D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355, 2218–2219 (2000).
Meier, C. R., Schlienger, R. G., Kraenzlin, M. E., Schlegel, B. & Jick, H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283, 3205–3210 (2000).
Shapiro, Y., Boaz, M., Matas, Z., Fux, A. & Shargorodsky, M. The association between the rennin–angiotensin–aldosterone system and arterial stiffness in young healthy subjects. Clin. Endocrinol. (Oxf.) 68, 510–512 (2008).
Shimizu, H. et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 22, 2465–2475 (2008).
Law, P. H., Sun, Y., Bhattacharya, S. K., Chhokar, V. S. & Weber, K. T. Diuretics and bone loss in rats with aldosteronism. J. Am. Coll. Cardiol. 46, 142–146 (2005).
Lynn, H., Kwok, T., Wong, S. Y., Woo, J. & Leung, P. C. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38, 584–588 (2006).
Price, P. A., Faus, S. A. & Williamson, M. K. Biphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler. Thromb. Vasc. Biol. 21, 817–824 (2001).
Luckman, S. P. et al. Nitrogen-containing biphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13, 581–589 (1998).
Su, J. Z., Fukuda, N., Kishioka, H., Hu, W. Y. & Kanmatsuse, K. Etidronate influences growth and phenotype of rat vascular smooth muscle cells. Pharmacol. Res. 46, 7–13 (2002).
Kanazawa, I. et al. Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am. J. Med. Sci. 339, 519–524 (2010).
Chow, J. T. et al. Abdominal aortic calcification, BMD, and bone microstructure: a population-based study. J. Bone Miner. Res. 23, 1601–1612 (2008).
Hyder, J. A. et al. Association of coronary artery and aortic calcium with lumbar bone density. The MESA Abdominal Aortic Calcium Study. Am. J. Epidemiol. 169, 186–194 (2009).
Choi, S. H. et al. Lower bone mineral density is associated with higher coronary calcification and coronary plaque burdens by multidetector row coronary computed tomography in pre- and postmenopausal women. Clin. Endocrinol. 71, 644–651 (2009).
Hak, A. E., Pols, H. A., van Hemert, A. M., Hofman, A. & Witteman, J. C. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler. Thromb. Vasc. Biol. 20, 1926–1931 (2000).
Adragao, T. et al. Low bone volume—a risk factor for coronary calcifications in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 4, 350–455 (2009).
Tanko, L. B., Bagger, Y. Z. & Christiansen, C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif. Tissue Int. 73, 15–20 (2003).
Reddy, J., Bilezikian, J. P., Smith, S. J. & Mosca, L. Reduced bone mineral density is associated with breast arterial calcification. J. Clin. Endocrinol. Metab. 93, 208–211 (2008).
Uyama, O., Yoshimoto, Y., Yamamoto, Y. & Kawai, A. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke 28, 1730–1732 (1997).
Sumino, H. et al. Relationship between carotid atherosclerosis and lumbar spine bone mineral density in postmenopausal women. Hypertens. Res. 31, 1191–1197 (2008).
Sumino, H. et al. Relationship between brachial arterial endothelial function and lumbar spine bone mineral density in postmenopausal women. Circ. J. 71, 1555–1559 (2007).
Seo, S. K. et al. Bone mineral density, arterial stiffness and coronary atherosclerosis in healthy postmenopausal women. Menopause 16, 937–943 (2009).
Szulc, P., Kiel, D. P. & Delmas, P. D. Calcifications in the abdominal aorta depicts fractures in men: MINOS study. J. Bone Miner. Res. 23, 95–102 (2008).
Schulz, E., Arfai, K., Liu, X., Sayre, J. & Gilsanz, V. Aortic calcification and the risk of osteoporosis and fractures. J. Clin. Endocrinol. Metab. 89, 4246–4253 (2004).
Bagger, Y. Z., Tanko, L. B., Alexandersen, P., Qin, G. & Christiansen, C. Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J. Intern. Med. 259, 598–605 (2006).
Naves, M., Rodriguez-Garcia, M., Diaz-Lopez, J. B., Gomez-Alonso, C. & Cannata-Andia, J. B. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos. Int. 19, 1161–1166 (2008).
Samelson, E. J. et al. Vascular calcification in middle-age and long term risk of hip fracture: the Framingham Study. J. Bone Miner. Res. 22, 1449–1454 (2007).
Farhat, G. N. et al. The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos. Int. 18, 999–1008 (2007).
Farhat, G. N. et al. Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging and body composition study. Calcif. Tissue Int. 79, 102–111 (2006).
Trivedi, D. P. & Khaw, K. T. Bone mineral density at the hip predicts mortality in elderly men. Osteoporos. Int. 12, 259–265 (2001).
Jorgensen, L., Engstad, T. & Jacobsen, B. Bone mineral density in acute stroke patients, low bone mineral density may predict first stroke in women. Stroke 32, 47–51 (2001).
Kiel, D. P. et al. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif. Tissue Int. 68, 271–276 (2001).
Marcovitz, P. A. et al. Usefulness of bone mineral density to predict significant coronary artery disease. Am. J. Cardiol. 96, 1059–1063 (2005).
Tanko, L. B. et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J. Bone Miner. Res. 20, 1912–1920 (2005).
Rodriguez-Garcia, M. et al. Vascular calcifications, vertebral fractures and mortality in haemodiaysis patients. Nephrol. Dial. Transplant. 24, 239–246 (2009).
Collins, T. C. et al. Peripheral arterial disease is associated with higher rates of hip bone loss and increased fracture risk in older men. Circulation 119, 2305–2312 (2009).
Laroche, M. et al. Bone mineral decrease in the leg with unilateral chronic occlusive arterial disease. Clin. Exp. Rheumatol. 21, 103–106 (2003).
Pennisi, P. et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos. Int. 15, 389–395 (2004).
Vogt, M. T., Cauley, J. A., Kuller, L. H. & Nevitt, M. C. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J. Bone Miner. Res. 12, 283–289 (1997).
Wong, S. Y. et al. Bone mineral density and the risk of peripheral arterial disease in men and women: results from Mr and Ms Os, Hong Kong. Osteoporos. Int. 16, 1933–1938 (2005).
van Diepen, S., Majumdar, S. R., Bakal, J. A., McAlister, F. A. & Ezekowitz, J. A. Heart failure is a risk factor for orthopaedic fracture: a population-based analysis of 16,294 patients. Circulation 118, 1946–1952 (2008).
Bolland, M. J., Grey, A., Avenell, A., Gamble, G. D. & Reid, I. R. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 342, d2040 (2011).
Hsia, J. et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 115, 846–854 (2007).
Lewis, J. R., Calver, J., Zhu, K., Flicker, L. & Prince, R. L. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J. Bone Miner. Res. 26, 35–41 (2011).
Wang, T. K. et al. Relationships between vascular calcification, calcium metabolism, bone density, and fractures. J. Bone Miner. Res. 25, 2777–2785 (2010).
Bolland, M. J. et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341, c3691 (2010).
Bolland, M. J. et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 336, 262–266 (2008).
Author information
Authors and Affiliations
Contributions
C. E. Lampropoulos and I. Papaioannou researched data for the article, all authors provided a substantial contribution to discussions of the content, C. E. Lampropoulos wrote the article, and C. E. Lampropoulos and D. P. D'Cruz reviewed and/or edited the article before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Lampropoulos, C., Papaioannou, I. & D'Cruz, D. Osteoporosis—a risk factor for cardiovascular disease?. Nat Rev Rheumatol 8, 587–598 (2012). https://doi.org/10.1038/nrrheum.2012.120
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.120
This article is cited by
-
Non-linear association of atherogenic index of plasma with bone mineral density a cross-sectional study
Lipids in Health and Disease (2024)
-
Vascular calcification: from the perspective of crosstalk
Molecular Biomedicine (2023)
-
Altered Caveolin-1 Dynamics Result in Divergent Mineralization Responses in Bone and Vascular Calcification
Cellular and Molecular Bioengineering (2023)
-
The Association of Cardiovascular Diseases Risk Scores and Osteosarcopenia Among Older Adult Populations: The Results of Bushehr Elderly Health (BEH) Program
Calcified Tissue International (2023)
-
Association of PFN1 Gene Polymorphisms with Bone Mineral Density, Bone Turnover Markers, and Osteoporotic Fractures in Chinese Population
Calcified Tissue International (2023)